Different Levels of Sialyl-Tn Antigen Expressed on MUC16 in Patients With Endometriosis and Ovarian Cancer
Open accessThe DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.
Abstract
Objective Although CA125 antigen is a useful marker for ovarian cancer, its expression is also elevated in endometriosis. The purpose of this study was to develop an assay method for evaluating differentially glycosylated MUC16 (CA125 core protein) in patients with endometriosis and ovarian cancer.Materials and methods We prepared MUC16-enriched fractions from peritoneal fluid of patients with endometriosis and conditioned medium of ovarian carcinoma-3 cells by gel filtration, and evaluated the expression of sialyl-Le, Tn, and sialyl-Tn antigens by dot blot analysis. A sandwich enzyme-linked immunosorbent assay was developed to measure the level of sialyl-Tn antigen expressed on MUC16 (sTn/MUC16). The level of sTn/MUC16 was compared between patients with endometriosis (n = 21) and ovarian cancer (n = 36) and in ovarian cancers with different clinical diagnostic criteria. Furthermore, distribution of MUC16 and sialyl-Tn antigen in ovarian cancer tissues was observed immunohistochemically.Results Sialyl-Tn antigen was markedly detectable in the MUC16-enriched fractions from conditioned medium of ovarian carcinoma-3 cells but negligible in those from the peritoneal fluid of the patients with endometriosis. The level of sTn/MUC16 determined by a sandwich enzyme-linked immunosorbent assay was significantly higher in the patients with ovarian cancer than that in the patients with endometriosis (P < 0.001). An elevated level of sTn/MUC16 was detected in 44% of the patients with ovarian cancer but not all the patients with endometriosis. This level increased more prominently in the patients with ovarian cancer than that of MUC16 as both the clinical stage and cytological grade advanced. An elevated level of sTn/MUC16 was frequently found in the patients with serous and endometrioid carcinomas. Consistent with this, sialyl-Tn antigen was colocalized with MUC16 in serous and endometrioid ovarian cancer tissues.Conclusions Estimation of the sTn/MUC16 level may be useful for discriminating endometriosis from ovarian cancer and for evaluating the clinical stage, cytological grade, and histological type of ovarian cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Revised American Society for Reproductive Medicine classification of endometriosis: 1996
American Society for Reproductive Medicine (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81391-x · Cited by 3,018
A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
Bast, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135
Reactivity of a monoclonal antibody with human ovarian carcinoma.
Bast, R. C., Feeney, M., Lazarus, H., Nadler, L. M., Colvin, R. B., & Knapp, R. C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110380 · Cited by 1,661 · cited 2×
“CA125 antigen was originally identified using a mono-clonal antibody, OC125.”
BackgroundMolecular Cloning of the CA125 Ovarian Cancer Antigen
Yin, B. W. T., & Lloyd, K. O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103554200 · Cited by 617 · cited 1×
“Molecular cloning of CA125 antigen revealed that it was encoded by theMUC16 gene and was a type I membrane glycoprotein comprising a long extracellular domain, a transmembrane domain, and a short cytoplasmic domain.(2,3) The extracellular domain of MUC16 is highly modified with a variety of N- and O-glycans,(4) which…”
BackgroundGubbels, J. A., Belisle, J., Onda, M., Rancourt, C., Migneault, M., Ho, M., Bera, T. K., Connor, J., Sathyanarayana, B. K., Lee, B., et al. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-50 · Cited by 422
CA 125: The past and the Future
Bast, R. C., Xu, F.-J., Yu, Y.-H., Barnhill, S., Zhang, Z., & Mills, G. B. (1998) · The International Journal of Biological Markers · doi:10.1177/172460089801300402 · Cited by 397 · cited 1×
“However, this marker exhibits a high false-positive rate for a number of benign conditions such as endometriosis.(13,14) Sialyl-Tn antigen (Neu5Ac>2-6GalNAc-O-Ser/Thr) is one of the tumor-associated mucin-type carbohydrate antigens.”
BackgroundBafna, S., Kaur, S., & Batra, S. K. (2010) · Oncogene · doi:10.1038/onc.2010.87 · Cited by 360
The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences
O’Brien, T. J., Beard, J. B., Underwood, L. J., Dennis, R. A., Santin, A. D., & York, L. (2001) · Tumor Biology · doi:10.1159/000050638 · Cited by 300 · cited 1×
“Molecular cloning of CA125 antigen revealed that it was encoded by theMUC16 gene and was a type I membrane glycoprotein comprising a long extracellular domain, a transmembrane domain, and a short cytoplasmic domain.(2,3) The extracellular domain of MUC16 is highly modified with a variety of N- and O-glycans,(4) which…”
BackgroundKlug, T. L., Bast, R. C., Niloff, J. M., KNAPP, R. C., & Zurawski, V. R. (1984) · PubMed · Cited by 298
Human Tumor Antigens Tn and Sialyl Tn Arise from Mutations in Cosmc
Ju, T., Lanneau, G. S., Gautam, T., Wang, Y., Xia, B., Stowell, S. R., Willard, M. T., Wang, W., Xia, J. Y., Zuna, R. E., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2345 · Cited by 292
Argüeso, P., Guzman-Aranguez, A., Mantelli, F., Cao, Z., Ricciuto, J., & Panjwani, N. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033332 · Cited by 257
Characterization of the Oligosaccharides Associated with the Human Ovarian Tumor Marker CA125
Kui Wong, N., Easton, R. L., Panico, M., Sutton-Smith, M., Morrison, J. C., Lattanzio, F. A., Morris, H. R., Clark, G. F., Dell, A., & Patankar, M. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302741200 · Cited by 238
Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes
Belisle, J. A., Horibata, S., Jennifer, G. A., Petrie, S., Kapur, A., André, S., Gabius, H.-J., Rancourt, C., Connor, J., Paulson, J. C., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-118 · Cited by 207
Kobayashi, H., Terao, T., & Kawashima, Y. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.95 · Cited by 160 · cited 2×
“Similar to the sTn/MUC16 level, the serum level of sialyl-Tn antigen in patients with ovarian cancer also increases as the clinical stage advances.(15,16) Consistent with the level of sTn/MUC16 observed on our ELISA, immunohistochemical studies revealed that MUC16 and sialyl-Tn antigen were clearly colocalized in ovar…”
BackgroundResultThe cancer antigen CA125 represents a novel counter receptor for galectin-1
Seelenmeyer, C., Wegehingel, S., Lechner, J., & Nickel, W. (2003) · Journal of Cell Science · doi:10.1242/jcs.00312 · Cited by 153
Chauhan, S. C., Singh, A. P., Ruiz, F., Johansson, S. L., Jain, M., Smith, L. M., Moniaux, N., & Batra, S. K. (2006) · Modern Pathology · doi:10.1038/modpathol.3800646 · Cited by 140
Ikehara, Y., Kojima, N., Kurosawa, N., Kudo, T., Kono, M., Nishihara, S., Issiki, S., Morozumi, K., Itzkowitz, S., Tsuda, T., et al. (1999) · Glycobiology · doi:10.1093/glycob/9.11.1213 · Cited by 139
Self-citationCA 125 in Benign Gynecological Conditions
Meden, H., & Fattahi-Meibodi, A. (1998) · The International Journal of Biological Markers · doi:10.1177/172460089801300411 · Cited by 122
Matsuda, A., Kuno, A., Kawamoto, T., Matsuzaki, H., Irimura, T., Ikehara, Y., Zen, Y., Nakanuma, Y., Yamamoto, M., Ohkohchi, N., et al. (2010) · Hepatology · doi:10.1002/hep.23654 · Cited by 98 · cited 1×
“Recently, it has been indicated that an approach targeting the specific glyco-alteration on some proteins may have great potential for improving the diagnostic accuracy for cancer prediction.(17,18) In this study, we found that sialyl-Le and Tn antigens, but not sialyl-Tn antigen, were mostly detectable in the MUC16-e…”
BackgroundSelf-citationMultilectin Assay for Detecting Fibrosis-Specific Glyco-Alteration by Means of Lectin Microarray
Kuno, A., Ikehara, Y., Tanaka, Y., Angata, T., Unno, S., Sogabe, M., Ozaki, H., Ito, K., Hirabayashi, J., Mizokami, M., et al. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.151340 · Cited by 76 · cited 1×
“Recently, it has been indicated that an approach targeting the specific glyco-alteration on some proteins may have great potential for improving the diagnostic accuracy for cancer prediction.(17,18) In this study, we found that sialyl-Le and Tn antigens, but not sialyl-Tn antigen, were mostly detectable in the MUC16-e…”
BackgroundSelf-citationDavidson, B., Gotlieb, W. H., Ben‐Baruch, G., Kopolovic, J., Goldberg, I., Nesland, J. M., Berner, A., Bjåmer, A., & Bryne, M. (2000) · Gynecologic Oncology · doi:10.1006/gyno.1999.5708 · Cited by 63
Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma.
Sekine, H., Hayes, D. F., Ohno, T., Keefe, K. A., Schaetzl, E., Bast, R. C., KNAPP, R. C., & Kufe, D. W. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.10.1355 · Cited by 47 · cited 1×
“With respect to mucin core protein, there have been some reports that MUC1 and MUC4 are expressed in mucinous ovarian carcinomas(29) and that the serum level of MUC1 is elevated in patients with ovarian cancer.(30) These findings suggest that sialyl-Tn antigen in mucinous ovarian carcinomas may be mostly carried on mu…”
ResultKobayashi, H., Terao, T., & Kawashima, Y. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.6.983 · Cited by 38 · cited 2×
“Similar to the sTn/MUC16 level, the serum level of sialyl-Tn antigen in patients with ovarian cancer also increases as the clinical stage advances.(15,16) Consistent with the level of sTn/MUC16 observed on our ELISA, immunohistochemical studies revealed that MUC16 and sialyl-Tn antigen were clearly colocalized in ovar…”
BackgroundResultOhno, S., Ohno, Y., Nakada, H., Suzuki, N., Soma, G., & Inoue, M. (2006) · PubMed · Cited by 32
Self-citationInoue, M., Fujita, M., Nakazawa, A., Ogawa, H., & Tanizawa, O. (1992) · Obstetrics and Gynecology · doi:10.1097/00006250-199203000-00022 · Cited by 30
Self-citationInoue, M., Fujita, M., Nakazawa, A., Ogawa, H., & Tanizawa, O. (1992) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(92)90679-d · Cited by 29
Self-citationBinding characteristics of an anti‐Siaα2–6GalNAcα‐Ser/Thr (sialyl Tn) monoclonal antibody (MLS 132)
Tanaka, N., Nakada, H., Inoue, M., & Yamashina, I. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00401.x · Cited by 19
Self-citationCA125 in peritoneal fluid of ovarian cancer patients
Vergote, I. B., Onsrud, M., Børmer, O. P., Sert, B. M., & Moen, M. H. (1992) · Gynecologic Oncology · doi:10.1016/0090-8258(92)90032-e · Cited by 18
Ligation of tumour-produced mucins to CD22 dramatically impairs splenic marginal zone B-cells
Toda, M., Hisano, R., Yurugi, H., Akita, K., Maruyama, K., Inoue, M., Adachi, T., Tsubata, T., & Nakada, H. (2008) · Biochemical Journal · doi:10.1042/bj20081241 · Cited by 18 · cited 1×
“An aliquot of the MUC16-enriched fraction prepared from the conditioned medium of OVCAR-3 cells was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by Western blot analysis as described previously.(23)”
MethodSelf-citationKitagawa, H., Nakada, H., Numata, Y., Kurosaka, A., Fukui, S., Funakoshi, I., Kawasaki, T., & Yamashina, I. (1988) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a122555 · Cited by 16
Self-citationNakada, H., Inoue, M., Numata, Y., Tanaka, N., Funakoshi, I., Fukui, S., & Yamashina, I. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)81481-0 · Cited by 7
Self-citation
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“The subset of cancer-derived molecules (e.g., CA125, Sialyl-Tn and CA19-9) that survive such clearance then become useful markers of disease progression (948) (949) (950) (951) .”
BackgroundMUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
Felder, M., Kapur, A., Gonzalez-Bosquet, J., Horibata, S., Heintz, J., Albrecht, R., Fass, L., Kaur, J., Hu, K., Shojaei, H., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-129 · Cited by 524
“Attempts to identify diseasespecific MUC16 glycoforms by glycomic analysis are producing interesting results that may enhance the diagnostic potential of this mucin [81-88].”
BackgroundAltered glycosylation in cancer: A promising target for biomarkers and therapeutics
Thomas, D., Rathinavel, A. K., & Radhakrishnan, P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188464 · Cited by 372
“The detection of STn antigen on MUC16 can be used as a diagnostic tool to discriminate endometriosis from ovarian cancer [31].”
BackgroundSimple Sugars to Complex Disease—Mucin-Type O-Glycans in Cancer
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2014.11.002 · Cited by 260
MUC16 as a novel target for cancer therapy
Aithal, A., Rauth, S., Kshirsagar, P., Shah, A., Lakshmanan, I., Junker, W. M., Jain, M., Ponnusamy, M. P., & Batra, S. K. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1498845 · Cited by 231
Metadata
- Authors
- Akita, K., Yoshida, S., Ikehara, Y., Shirakawa, S., Toda, M., Inoue, M., Kitawaki, J., Nakanishi, H., Narimatsu, H., & Nakada, H.
- Affiliations
- Kyoto Sangyo University (JP)
- National Institute of Advanced Industrial Science and Technology (JP)
- Kyoto Prefectural University of Medicine (JP)
- Aichi Cancer Center Research Institute (JP)
- Venue
- International Journal of Gynecological Cancer
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 22
- Issue
- 4
- Pages
- 531-538
- ISSN
- 1048-891X (ISSN-L)
- OpenAlex
- W2323039355
- Cited by
- 54
- References
- 33
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 7 · 2023: 6 · 2022: 7 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 9 · 2015: 3 · 2014: 5 · 2013: 1 · 2012: 1
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor)
- Locations
- International Journal of Gynecological Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (24592480, 24590498, 21590457)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- sialyl-Tn antigen, CA125, endometriosis, ovarian cancer, glycosylation, Tn antigen, peritoneal fluid, serous carcinoma, endometrioid carcinoma, tumor markers, clinical stage, differential diagnosis, sandwich ELISA, immunohistochemistry
- MeSH terms
- Adult, Aged, Ascitic Fluid, Endometriosis, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunoenzyme Techniques, Membrane Proteins, Middle Aged, Neoplasm Staging, Oligosaccharides, Ovarian Neoplasms, Prognosis, Tumor Cells, Cultured, Biomarkers, Tumor, Blotting, Western, Antigens, Tumor-Associated, Carbohydrate, Culture Media, Conditioned, CA-125 Antigen, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.